Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board
19 juil. 2022 03h01 HE
|
Mainz BioMed NV
Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos...
Mainz Biomed Today to Provide Corporate Update for First Half of 2022
12 juil. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, July 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Provides Corporate Update for First Half of 2022
05 juil. 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, July 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
28 juin 2022 03h01 HE
|
Mainz BioMed NV
Multi-center clinical trial impacting ColoAlert’s profile for FDA submissionOn track to report results by early 2023 BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 (GLOBE NEWSWIRE) -- Mainz...
Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission
14 juin 2022 03h01 HE
|
Mainz BioMed NV
Jane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices Will manage the design and logistical...
Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance
01 juin 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)
19 mai 2022 03h01 HE
|
Mainz BioMed NV
Dante Labs is a Global Leader in Genomics and Precision MedicineMainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and...
Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference
17 mai 2022 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Host Key Opinion Leader Event at DDW 2022
09 mai 2022 08h01 HE
|
Mainz BioMed NV
Digestive Disease Week is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery ...
Mainz Biomed Provides Product Development Update on PancAlert
05 mai 2022 03h01 HE
|
Mainz BioMed NV
Novel Screening Test for Pancreatic Cancer Funded by the German GovernmentAchieved Key Project Milestones; Next Phase of Development Launched BERKELEY, Calif. and MAINZ, Germany, May 05, 2022 ...